B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Global Study Management Senior - Associate, Global CTA

Full-TimePosted on 10/23/2026
No salary listed
Mid
Bachelor's
Remote in Australia+1 moreMore locations: Sydney NSW, Australia
RemoteLimited travel may be required.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor’s or higher degree in a scientific or healthcare discipline is required; a higher degree is preferred.
  • Proficiency in Microsoft Office Suite, including Excel, PowerPoint, and Project.
  • Knowledge of clinical operations methodologies and understanding of operational aspects of clinical study processes.
  • At least 3 years of experience in clinical research within the biotechnology, pharmaceutical, or contract research organization industry.
Responsibilities
  • Support the Global Clinical Study Manager in global study delivery, ensuring delegated study components are executed to specified quality standards within timelines and budget.
  • Support alignment of study goals with clinical operations goals and objectives under the direction of the Global Clinical Study Manager.
  • Support study vendor management and other assigned study management activities.
  • Support organization and logistics for cross-functional Clinical Study Team meetings.
  • Collaborate with the Global Clinical Study Manager, Regional Clinical Trial Management Associates, and other global and regional stakeholders.
  • Interpret and implement regulatory and International Council for Harmonisation Good Clinical Practice guidelines in clinical study operations.
  • Build knowledge of global clinical trial operations under the guidance of the Global Clinical Study Manager.
  • Contribute to Global Study Management Associate task force initiatives and cross-functional projects, supporting process improvement, standardization, and implementation activities.
  • Create and maintain study-level SharePoint sites and Clinical Study Team distribution lists.
  • Set up studies in appropriate systems, such as electronic Trial Master File and Clinical Trial Management System, and keep study-level information up to date.
  • Ensure system access is appropriately granted and managed throughout the study life cycle, and support user account management for study systems.
  • Support development of study plans.
  • Review study-related documents as delegated, including clinical protocols, informed consent forms, investigator brochures, pharmacy manuals, monitoring plans, laboratory manuals, patient diaries, case report forms, case report form completion guidelines, and other relevant study plans and charters.
  • Organize study-specific investigator meetings under the supervision of the Global Clinical Study Manager.
  • Support creation and review of site feasibility assessments required for study participation.
  • Manage and track key study deliverables, including screening, enrollment, biological samples and images, data flow, and protocol deviations, in relevant systems with Regional Clinical Trial Management Associates.
  • Prepare metrics and updates on key deliverables for management using information available in relevant systems.
  • Support preparation of study newsletters and other study-conduct correspondence, including frequently asked questions and lessons learned, in collaboration with the study team.
  • Support the Trial Master File specialist with study-level Trial Master File creation and, as required, maintain the study-level Trial Master File, including regular review and quality control of documents according to the study Trial Master File quality-control plan.
  • Support study drug forecasts and overall study drug supply activities with the Global Clinical Study Manager and Global Clinical Supplies.
  • Support overall data cleaning activities and follow up on outstanding information.
  • Support the Global Clinical Study Manager with planning and execution of the Clinical Study Report.
  • Support identification of operational risks and issues and work with the Global Clinical Study Manager to recommend solutions for discussion with appropriate team leadership.
  • Learn and share best practices in clinical operations methodologies, systems, and processes, emphasizing quality and compliance.
  • Suggest improvements to enhance efficiency and the quality of work performed on assigned projects.
  • Support development of global study tools, work instructions, and standard operating procedures.
  • Support selection and setup of vendors for global outsourced activities.
  • Support study budget management, including purchase order setup and payment invoice tracking throughout study life cycles.
  • May mentor junior team members and support onboarding of new hires.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
BeOne Medicines looks 13% undervalued at $377.63 as ESMO data lifts sentiment

BeOne Medicines (ONC) is drawing investor attention after new ESMO 2026 data on TEVIMBRA plus ZIIHERA and chemotherapy in HER2-positive gastroesophageal cancer. The data showed longer-term survival figures. The shares have gained 15.87% over 90 days and 21.42% so far this year. Three-year total shareholder return is about 121.55%. A widely followed narrative puts fair value at $433.02 against a last close of $377.63, implying the stock is 13% undervalued. It cites 87% revenue growth in Europe, 168% growth in the rest of the world, and approvals in more than 75 countries. Earnings tell a different story. The price-to-earnings ratio is 65.5x, against a fair ratio of 35.2x and a peer average of about 29.2x. Risks include BRUKINSA concentration and late-stage trial delays.

Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.